Veeva Systems
VEEV
$158.22
-0.17%
Veeva Systems Inc. is the global leader in providing cloud-based software solutions specifically tailored for the life sciences industry, with core products including its Veeva CRM platform for salesforce management and Veeva Vault for content management. The company has established itself as a dominant, best-of-breed platform player by displacing legacy enterprise systems with its specialized, compliant offerings for pharmaceutical and biotech clients. The current investor narrative is dominated by a significant stock price decline, creating a debate between viewing this as a compelling long-term buying opportunity due to Veeva's entrenched market position and growth runway versus concerns over near-term execution or broader market pressures on growth stocks.…
VEEV
Veeva Systems
$158.22
Related headlines
VEEV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $205.69 and implied upside of +30.0% versus the current price.
Average Target
$205.69
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$127 - $206
Analyst target range
Veeva is covered by at least 9 analysts, as evidenced by the detailed institutional ratings data. The consensus sentiment leans bullish, with recent actions including multiple 'Buy', 'Overweight', and 'Outperform' ratings from firms like Citigroup, TD Cowen, Truist Securities, Piper Sandler, Wells Fargo, and RBC Capital. Neutral stances are held by Evercore ISI, UBS, Morgan Stanley, and Canaccord Genuity. The average analyst revenue estimate for the coming period is $5.88 billion, with a tight range between $5.81 billion and $5.97 billion, indicating strong consensus on the top-line outlook. The implied upside or downside to a consensus price target cannot be calculated precisely as an average target price is not provided in the data. However, the narrow range of revenue estimates and the prevalence of bullish ratings suggest analysts see limited fundamental downside from current levels. The recent news highlighting a 35% stock decline as a buying opportunity aligns with this generally constructive analyst view. The lack of downgrades in the recent institutional ratings data, with all firms maintaining their previous ratings, signals stability in analyst conviction despite the stock's sharp price decline.
Bulls vs Bears: VEEV Investment Factors
The investment debate for Veeva hinges on a clash between deteriorating price momentum and intact business fundamentals. The bear case, currently supported by stronger near-term evidence, is driven by a severe technical breakdown and macro-induced de-rating of growth stocks. The bull case rests on the company's demonstrable operational strength, including 16% revenue growth, 29% net margins, and a fortress balance sheet. The single most important tension is whether the stock's 45% decline over six months has fully priced in macro and sentiment risks, or if the broken technical picture and still-elevated valuation multiples foreshadow further downside. The resolution of this tension depends on whether Veeva's next earnings report can reaffirm its growth trajectory and halt the momentum-driven selling.
Bullish
- Dominant Market Position: Veeva is the global leader in cloud software for the life sciences industry, a compliance-heavy niche with high switching costs. This entrenched position, displacing legacy systems, provides a durable competitive moat and a clear path to doubling revenue by 2030 as cited by recent analysis.
- Exceptional Profitability & Margins: The company exhibits best-in-class financial health with a Q4 net margin of 29.21% and a gross margin of 74.46%. This high profitability, coupled with a pristine balance sheet (Debt/Equity of 0.013 and $1.39B in TTM FCF), provides resilience and internal funding for growth.
- Strong & Consistent Revenue Growth: Veeva continues to deliver solid top-line expansion, with Q4 FY2026 revenue of $835.95M representing 15.96% YoY growth. Quarterly revenue has grown sequentially from $759M to $836M over the past year, demonstrating consistent execution in its core market.
- Significant Valuation Compression: The stock has undergone a severe de-rating, down 45% over 6 months and trading just 9% above its 52-week low. Its trailing PE of 36.72x is well below historical highs above 70x, suggesting much of the multiple compression for a growth stock may be behind it.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend with a 6-month decline of -45.01% and a 3-month drop of -27.42%. It has severely underperformed the market (Relative Strength -31.01 over 3M) and sits near 52-week lows, indicating persistent selling pressure and broken investor confidence.
- Elevated Valuation Despite Crash: Even after the steep decline, Veeva's trailing PE of 36.72x and PS ratio of 10.44x remain high for a software company, implying continued premium pricing. The PEG ratio of 1.42 suggests the stock is fairly valued relative to its growth, not clearly undervalued.
- Growth Stock Macro Sensitivity: With a beta of 1.103, Veeva is more volatile than the market and is exposed to sector rotation away from growth stocks, as highlighted by recent news on geopolitical uncertainty favoring defensive sectors. This macro headwind has been a primary driver of its 50.55% maximum drawdown.
- Potential Growth Deceleration Risk: While current growth is solid at ~16% YoY, the forward PE of 16.30x embeds high expectations for future earnings expansion. Any miss on these expectations or a slowdown in the life sciences IT spending cycle could trigger further multiple compression.
VEEV Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -29.24% and a more severe 6-month decline of -45.01%. Currently trading at $161.13, the price sits just 9% above its 52-week low of $148.05, positioning it at the very bottom of its annual range and signaling deep investor pessimism, though it may also indicate an oversold condition. Recent momentum shows continued weakness, with a 1-month decline of -9.53% and a 3-month drop of -27.42%, both significantly underperforming the broader market as indicated by relative strength figures of -18.23 and -31.01, respectively, suggesting the downtrend is accelerating without signs of a near-term reversal. Key technical levels are clearly defined, with immediate support at the 52-week low of $148.05 and major resistance far above at the 52-week high of $310.50. A decisive break below the $148 support could trigger further technical selling, while any meaningful recovery would need to overcome significant overhead supply. The stock's beta of 1.103 indicates it is approximately 10% more volatile than the market, which, combined with a maximum drawdown of -50.55%, underscores its heightened risk profile during this bearish phase and necessitates careful position sizing. The price action over the last 180 days illustrates a cascade from the $290s in late October 2025 to the $150s by April 2026, punctuated by severe sell-offs in November and February. The recent bounce from the April low of $151.43 to the current $161.13 represents a modest 6.4% recovery, but it remains within the context of the dominant downtrend. Volume data shows an average of 1.62 million shares traded, but the absence of a clear volume spike on the recent low suggests capitulation may not yet be complete.
Beta
1.10
1.10x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-31.7%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | -10.1% | +12.6% |
| 3m | -24.6% | +2.5% |
| 6m | -45.7% | +4.3% |
| 1y | -31.7% | +28.4% |
| ytd | -27.9% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Veeva's revenue trajectory remains solidly positive, with Q4 FY2026 revenue of $835.95 million representing a 15.96% year-over-year growth. Sequentially, revenue has grown from $759.04 million in Q1 to $835.95 million in Q4, demonstrating consistent quarterly expansion. The Subscription Services segment for Veeva Commercial Cloud, at $644.63 million, is the primary growth driver, though the $95.04 million Professional Services segment also contributes. This growth trend supports the investment case for a company gaining share in a specialized, compliance-heavy market. The company is highly profitable, with Q4 net income of $244.20 million and a robust net margin of 29.21%. Gross margins are exceptionally strong at 74.46% for the quarter, consistent with the software-as-a-service model. Operating margins are also healthy at 29.41%. Profitability has been stable, with net income growing from $228.19 million in Q1 to $244.20 million in Q4, indicating disciplined cost management alongside revenue growth, which is a key strength in the current environment. Veeva's balance sheet is exceptionally strong, featuring a minimal debt-to-equity ratio of 0.013 and a high current ratio of 4.89, indicating ample liquidity. The company generates substantial cash, with trailing twelve-month free cash flow of $1.39 billion. Return on equity stands at 12.60%, and return on assets is 7.25%, both reflecting efficient use of capital. This pristine financial health means Veeva can fund its growth internally and is well-positioned to weather economic uncertainty or invest in strategic opportunities.
Quarterly Revenue
$835951000.0B
2026-01
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given Veeva's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 36.72x, which is significantly higher than the forward PE of 16.30x. This wide gap implies the market expects strong earnings growth in the coming year, as the forward multiple prices in the anticipated bottom-line expansion. Comparing Veeva's valuation to industry averages is challenging as specific sector multiples are not provided in the data. However, a trailing PE of 36.72x is typically considered elevated for a mature software company, suggesting the market continues to price in a premium for Veeva's leadership position, high margins, and predictable growth within the life sciences niche. The PEG ratio of 1.42, based on trailing earnings, indicates the stock may be fairly valued relative to its growth rate. Historically, Veeva's valuation has compressed significantly from its peak. The current trailing PE of 36.72x is below the historical highs seen in recent years, such as the 57.86x recorded in Q2 2025 and the 73.36x from mid-2023. This de-rating places the stock nearer the middle-to-lower end of its own historical valuation band over the past few years, suggesting much of the multiple compression may have already occurred, though it remains above the low-teens forward PE implied by analyst estimates for future earnings.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 34x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Veeva's primary financial risk is not insolvency—its balance sheet is pristine with minimal debt and $1.39B in TTM FCF—but valuation compression if its growth rate decelerates. The stock trades at a trailing PE of 36.7x, which demands sustained high growth to justify. A decline in revenue growth below the current ~16% YoY could trigger significant multiple contraction. Furthermore, while margins are robust, any increase in R&D or sales costs to maintain competitive advantage could pressure the 29% net margin. Revenue concentration in the life sciences sector, though a strength, is a single-point failure risk if sector spending slows.
Market & Competitive Risks: The most acute external risk is continued de-rating of growth stocks in a higher-rate environment, as evidenced by Veeva's 50.55% max drawdown and severe underperformance versus the S&P 500 (-59.8% relative strength over 1 year). Its beta of 1.103 confirms above-market volatility, making it vulnerable to broader market sell-offs. Competitively, while Veeva's niche focus provides a moat, larger enterprise software vendors or new regulatory hurdles could challenge its dominance. The current valuation (PS ratio of 10.44x) remains at a premium, leaving room for further compression if investor appetite for software stocks wanes.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown coinciding with a sustained risk-off environment for growth stocks. This could see Veeva miss revenue estimates, leading to analyst downgrades, while simultaneously experiencing multiple compression towards its historical lows. A realistic downside target is a retest and break below the 52-week low of $148.05, potentially extending to the $130-$140 range if sentiment deteriorates further. From the current price of $161.13, this implies a potential loss of 8-19% to the immediate support level, and a more severe decline of 25-30% in a prolonged bear case, revisiting the lows of the 2022 cycle.
